Chromocell Therapeutics (CHRO) Competitors $1.59 +0.11 (+7.43%) Closing price 03/28/2025 03:59 PM EasternExtended Trading$1.58 -0.02 (-0.94%) As of 03/28/2025 07:36 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock CHRO vs. XCUR, NRXP, LVTX, INKT, GBIO, CASI, CLNN, OVID, ATHE, and PASGShould you be buying Chromocell Therapeutics stock or one of its competitors? The main competitors of Chromocell Therapeutics include Exicure (XCUR), NRx Pharmaceuticals (NRXP), LAVA Therapeutics (LVTX), MiNK Therapeutics (INKT), Generation Bio (GBIO), CASI Pharmaceuticals (CASI), Clene (CLNN), Ovid Therapeutics (OVID), Alterity Therapeutics (ATHE), and Passage Bio (PASG). These companies are all part of the "pharmaceutical products" industry. Chromocell Therapeutics vs. Exicure NRx Pharmaceuticals LAVA Therapeutics MiNK Therapeutics Generation Bio CASI Pharmaceuticals Clene Ovid Therapeutics Alterity Therapeutics Passage Bio Chromocell Therapeutics (NYSE:CHRO) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, community ranking, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk. Does the media refer more to CHRO or XCUR? In the previous week, Exicure had 4 more articles in the media than Chromocell Therapeutics. MarketBeat recorded 4 mentions for Exicure and 0 mentions for Chromocell Therapeutics. Exicure's average media sentiment score of 0.57 beat Chromocell Therapeutics' score of 0.00 indicating that Exicure is being referred to more favorably in the news media. Company Overall Sentiment Chromocell Therapeutics Neutral Exicure Positive Do insiders and institutionals have more ownership in CHRO or XCUR? 78.0% of Chromocell Therapeutics shares are held by institutional investors. Comparatively, 42.8% of Exicure shares are held by institutional investors. 16.4% of Chromocell Therapeutics shares are held by insiders. Comparatively, 8.4% of Exicure shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. Does the MarketBeat Community prefer CHRO or XCUR? Exicure received 8 more outperform votes than Chromocell Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Chromocell Therapeutics an outperform vote while only 47.37% of users gave Exicure an outperform vote. CompanyUnderperformOutperformChromocell TherapeuticsOutperform Votes1100.00% Underperform VotesNo VotesExicureOutperform Votes947.37% Underperform Votes1052.63% Which has preferable valuation and earnings, CHRO or XCUR? Chromocell Therapeutics has higher earnings, but lower revenue than Exicure. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioChromocell TherapeuticsN/AN/A-$7.38MN/AN/AExicure$500K72.92-$16.91M-$4.81-2.91 Do analysts rate CHRO or XCUR? Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Chromocell Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00Exicure 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is CHRO or XCUR more profitable? Chromocell Therapeutics' return on equity of 0.00% beat Exicure's return on equity.Company Net Margins Return on Equity Return on Assets Chromocell TherapeuticsN/A N/A -453.90% Exicure N/A -190.90%-36.75% SummaryChromocell Therapeutics beats Exicure on 7 of the 12 factors compared between the two stocks. Remove Ads Get Chromocell Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CHRO and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CHRO vs. The Competition Export to ExcelMetricChromocell TherapeuticsBiological Products IndustryMedical SectorNYSE ExchangeMarket Cap$9.59M$3.03B$5.63B$19.40BDividend YieldN/A1.55%5.33%3.76%P/E RatioN/A30.4523.5833.06Price / SalesN/A431.82388.2326.59Price / CashN/A168.6838.1717.55Price / Book-0.963.926.894.53Net Income-$7.38M-$71.95M$3.20B$1.02B7 Day Performance1.27%-5.68%-3.06%-1.30%1 Month Performance-22.44%-12.09%1.51%-4.04%1 Year Performance-39.31%-27.90%9.37%2.55% Chromocell Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CHROChromocell TherapeuticsN/A$1.59+7.4%N/A-39.3%$9.59MN/A0.004Gap DownXCURExicure1.2484 of 5 stars$13.57-3.4%N/A+2,225.9%$35.36M$500,000.00-6.5650Short Interest ↑News CoverageGap DownNRXPNRx Pharmaceuticals2.5966 of 5 stars$2.07-0.5%$31.67+1,429.8%-95.7%$35.02MN/A-0.972LVTXLAVA Therapeutics2.4784 of 5 stars$1.30flat$3.17+143.6%-61.3%$34.19M$7.35M-1.2660Earnings ReportShort Interest ↓News CoverageINKTMiNK Therapeutics2.2299 of 5 stars$8.57-5.8%$37.50+337.6%-0.6%$33.99MN/A-2.2030GBIOGeneration Bio4.2925 of 5 stars$0.50-1.5%$7.33+1,379.7%-89.5%$33.21M$19.89M-0.23150Short Interest ↓Positive NewsCASICASI Pharmaceuticals4.3228 of 5 stars$2.12-4.1%$6.00+183.0%-40.3%$32.85M$22.06M-0.95180Analyst ForecastShort Interest ↓CLNNClene3.4756 of 5 stars$3.92-5.3%$55.25+1,309.4%-62.2%$32.64M$421,000.00-0.74100Earnings ReportShort Interest ↓Analyst RevisionNews CoverageOVIDOvid Therapeutics4.4478 of 5 stars$0.44+4.5%$3.03+582.7%-88.5%$31.58M$566,000.00-0.9560Analyst RevisionATHEAlterity Therapeutics2.4045 of 5 stars$3.54-6.1%$12.00+239.0%+66.2%$31.39MN/A0.0010Short Interest ↓News CoveragePASGPassage Bio3.2354 of 5 stars$0.50-0.2%$7.50+1,400.3%-71.8%$31.07MN/A-0.43130Positive NewsGap Down Remove Ads Related Companies and Tools Related Companies Exicure Competitors NRx Pharmaceuticals Competitors LAVA Therapeutics Competitors MiNK Therapeutics Competitors Generation Bio Competitors CASI Pharmaceuticals Competitors Clene Competitors Ovid Therapeutics Competitors Alterity Therapeutics Competitors Passage Bio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NYSE:CHRO) was last updated on 3/30/2025 by MarketBeat.com Staff From Our PartnersA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredNew “Trump” currency proposed in DCAccording to one of the most connected men in Washington… A surprising new bill was just introduced in Wash...Paradigm Press | SponsoredNvidia’s CEO: “This Will Be a Multitrillion-Dollar Industry."If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon’s ‘Strike Squad’ sends these 9 stocks soaring?Elon Musk's DOGE 'strike squad' just revealed it's speeding up the rollout of a radical technology across the ...Altimetry | SponsoredDoomed: These 50 Stocks Will Die Under Trump’s MAGA policies.Remember Kodak? Sears? Circuit City? They all failed to adapt to the changing times. Now, history is abo...Banyan Hill Publishing | SponsoredIs Trump Secretly Pumping Up Elon’s New AI Venture?President Trump just bought a Tesla - right in front of the White House. But what most investors don't real...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chromocell Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chromocell Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy CHRO Stock Free CHRO Stock Alerts